pseudoephedrine hydrochloride

CLINICAL USE

Nasal decongestant

DOSE IN NORMAL RENAL FUNCTION

60 mg 4 times a day

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :201.7

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data

%Excreted unchanged in urine &nbsp &nbsp : 90–98

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :2–3

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :5.5 (depends on pH of urine)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function. Use with caution

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAdrenergic neurone blockers: antagonise hypotensive effect of adrenergic neurone blockers

Antibacterials: risk of hypertensive crisis with linezolid

Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide

Dopaminergics: avoid concomitant use with rasagiline

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

5–20% is removed by haemodialysis Increased risk of developing hypertension in patients with GFR<20 mL/min

Tags: post-by-auto-php